DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

Stock Information for RepliCel Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RepliCel Life Sciences Inc.

Canadian Investment Regulatory Organization Trade Resumption - RP
Canadian Investment Regulatory Organization Trading Halt - RP
Canadian Investment Regulatory Organization Trading Halt - RP
TSX Venture Exchange Stock Maintenance Bulletins
RepliCel Provides Corporate Update
RepliCel Announces Material Patent Milestones in Key Markets
RepliCel's Manufacturing Inspected by Japan's PMDA
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.